These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23129656)

  • 1. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
    Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
    Tanaka N; Yoshida H; Suzuki Y; Harigaya K
    Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
    Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
    Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cooperation between hMena overexpression and HER2 signalling in breast cancer.
    Di Modugno F; Mottolese M; DeMonte L; Trono P; Balsamo M; Conidi A; Melucci E; Terrenato I; Belleudi F; Torrisi MR; Alessio M; Santoni A; Nisticò P
    PLoS One; 2010 Dec; 5(12):e15852. PubMed ID: 21209853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
    Pino MS; Balsamo M; Di Modugno F; Mottolese M; Alessio M; Melucci E; Milella M; McConkey DJ; Philippar U; Gertler FB; Natali PG; Nisticò P
    Clin Cancer Res; 2008 Aug; 14(15):4943-50. PubMed ID: 18676769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.
    Bria E; Di Modugno F; Sperduti I; Iapicca P; Visca P; Alessandrini G; Antoniani B; Pilotto S; Ludovini V; Vannucci J; Bellezza G; Sidoni A; Tortora G; Radisky DC; Crinò L; Cognetti F; Facciolo F; Mottolese M; Milella M; Nisticò P
    Oncotarget; 2014 Nov; 5(22):11054-63. PubMed ID: 25373410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
    Di Modugno F; Spada S; Palermo B; Visca P; Iapicca P; Di Carlo A; Antoniani B; Sperduti I; Di Benedetto A; Terrenato I; Mottolese M; Gandolfi F; Facciolo F; Chen EI; Schwartz MA; Santoni A; Bissell MJ; Nisticò P
    Oncogene; 2018 Oct; 37(42):5605-5617. PubMed ID: 29907768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
    Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
    EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome.
    Melchionna R; Iapicca P; Di Modugno F; Trono P; Sperduti I; Fassan M; Cataldo I; Rusev BC; Lawlor RT; Diodoro MG; Milella M; Grazi GL; Bissell MJ; Scarpa A; Nisticò P
    Oncoimmunology; 2016; 5(12):e1221556. PubMed ID: 28123868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLMEEMSAL epitope common in different isoforms of hMena elicits in vitro activation of cytotoxic T cells and stimulates specific antitumor immunity in BALB/c mice.
    Don-López CA; Monroy-García A; Weiss-Steider B; Rocha-Zavaleta L; Hernández-Montes J; García-Rocha R; Mora-García ML
    Int Immunopharmacol; 2018 Mar; 56():291-300. PubMed ID: 29414664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behavior.
    Balsamo M; Mondal C; Carmona G; McClain LM; Riquelme DN; Tadros J; Ma D; Vasile E; Condeelis JS; Lauffenburger DA; Gertler FB
    Sci Rep; 2016 Oct; 6():35298. PubMed ID: 27748415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
    Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.
    Di Modugno F; Caprara V; Chellini L; Tocci P; Spadaro F; Ferrandina G; Sacconi A; Blandino G; Nisticò P; Bagnato A; Rosanò L
    Proc Natl Acad Sci U S A; 2018 Mar; 115(12):3132-3137. PubMed ID: 29439204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of human ortholog of mammalian enabled (hMena) is associated with the expression of mutant p53 protein in human breast cancers.
    Toyoda A; Yokota A; Saito T; Kawana H; Higashi M; Suzuki Y; Tanaka T; Kitagawa M; Harigaya K
    Int J Oncol; 2011 Jan; 38(1):89-96. PubMed ID: 21109929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
    Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
    Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition.
    Arima Y; Inoue Y; Shibata T; Hayashi H; Nagano O; Saya H; Taya Y
    Cancer Res; 2008 Jul; 68(13):5104-12. PubMed ID: 18593909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.
    Warzecha CC; Sato TK; Nabet B; Hogenesch JB; Carstens RP
    Mol Cell; 2009 Mar; 33(5):591-601. PubMed ID: 19285943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
    Vadlamudi Y; Dey DK; Kang SC
    Curr Cancer Drug Targets; 2020; 20(9):654-665. PubMed ID: 32564755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression.
    Brown RL; Reinke LM; Damerow MS; Perez D; Chodosh LA; Yang J; Cheng C
    J Clin Invest; 2011 Mar; 121(3):1064-74. PubMed ID: 21393860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.